Showing results (151-160 of 177) with videos related to
Sort By:
Pageof 18
Alimentary Pharmacology & Therapeutics|August 12, 2025
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of TreatmentGrace Lai-Hung Wong, Edward Gane, Calvin Q Pan, et al.Journal of Hepatology|December 10, 2017
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studiesChristophe Hezode, Nancy Reau, Evguenia S Svarovskaia, et al.Journal of Hepatology|May 17, 2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP studyDonna M Evon, Souvik Sarkar, Jipcy Amador, et al.Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.JHEP Reports : Innovation in Hepatology|August 9, 2023
Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virusPhilippa C Matthews, Ponsiano Ocama, Su Wang, et al.Scientific Reports|July 21, 2019
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patientsOndrej Podlaha, Edward Gane, Maurizia Brunetto, et al.Antimicrobial Agents and Chemotherapy|July 25, 2018
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B InfectionAndrea L Cathcart, Henry Lik-Yuen Chan, Neeru Bhardwaj, et al.Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.Journal of Clinical Gastroenterology|November 24, 2020
WGO Guidance for the Care of Patients With COVID-19 and Liver DiseaseSaeed Hamid, Mario R Alvares da Silva, Kelly W Burak, et al.Pageof 18